Gilead-Yuhan hold Korean ‘Genvoya’ Launch Event

Published: 2017-02-16 15:08:23

Updated: 2017-02-16 15:08:23

Gilead Sciences Korea(CEO Seung-Woo Lee) and Yuhan Corporation(CEO Jung-Hee Lee) announced that they held the product launch event for the new one-pill, combination HIV treatment ‘Genvoya(elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg, Tenofovir alafenamide 10mg)’ on the 13^th.

Taking the event as a chance, the two companies is planning to successfully settle the product in the Korea...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.